Rubicon Water Limited $RWL $RWL.AX is an irrigation efficiency hardware and software company. They've built out from Australia into US, Europe and recently China and India - big markets. After successfully IPO'ing this month, they're up 75%.
"Water water everywhere, but not a drop to drink", Coleridge poem.
2. Story starts at food security.
With a growing population and increasing wealth, we simply have a need for more food production. This trend is not going to stabilise any time soon.
3. After the green revolution, there's the blue revolution.
Green revolution was all about improving land productivity through fertilizers, seed improvements, genetics, etc. It massively improved our total productivity, though also with some side effects. Here's cereals:
4. Blue revolution is amongst us.
This focuses on improving water efficiency. Accessible surface water is only 0.3% of all water (rest is salty), and ~70% of that is used for agriculture. And water scarcity is only getting worse, so irrigated agriculture needs to improve.
5. Irrigated agriculture market is growing.
The market growth rates well and truly passes my 'baked beans test' - it is only a small TAM, but growing at ~20% CAGR to around $1.2bn by FY26 according to Rubicon.
6. Australia once at the forefront.
Australia, California and Israel were early adopters of irrigation efficiency due to the climate. This involved creating water markets (incentives), shifting from flooding surfaces to targeted drip irrigation etc.
7. Emerging markets.
The big and growing markets are unsurprisingly in Asia, where the tech has not been deployed. Central Asia still uses pre-Soviet systems; South Asia lacks the physical capital; and East Asia is in the midst of modernisation.
8. Rubicon's products - complex version.
Rubicon is a water technology solutions business that designs, manufactures, installs and maintains irrigation automation software and hardware. Here's their schematic.
9. Rubicon's products - simple version.
Rubicon essentially builds gates, put sensors on them, and has software to open/close when the water is needed. This is an example of their FlumeGate.
10. Expanding footprint.
Recently Rubicon expanded from Australia into China (2018) and India (2020) with joint ventures. This has expanded their manufacturing and reach.
11. Diversifying revenue.
These expansions are already paying off in terms of dramatically increasing revenue from Asia. Look at these awesome charts!
12. Cool story, bro.
So that's the story. A lot of the +75% growth is no doubt based on that. But if you've read this far, you know that's not where the story ends.
Borat's sister in Kazakhstan used 19th century Soviet irrigation technology - a concrete channel.
13. Two steps forward, one step back.
The percentage growth in Asia has been because of the decline by Australia. The total revenue has been relatively flat - particularly if you factor in ~$5m of FY20 sales pushed to FY21 due to Covid.
14. Margins being squeezed.
When looking at the EBITDA, you can see the same trends but slightly worse. Reality is that margins for India and China are much lower and competition is stronger.
15. Where's the operating earnings?
The cash flow statement illuminates something very interesting. Despite the operating earnings, they are draining cash. It's all going into working capital. Hmm.
16. Trade and other receivables ballooning.
Bare with me, as this is from a separate annual report filing. But you can see here a huge increase in unpaid trade receivables.. maybe nothing to worry about.
17. Reducing impairments on increasing loans.
While current receivables have 5xed since listing, their late payments are now at $5m. Meanwhile, they've reduced the impairment by 30%. I'm sure it's all fine.
18. Future profits in decline.
Putting aside Deloitte's fantastic record here. The profit is waning, and this is a bit of a trend. So we're looking at around $7.5m forecast for FY21, of which only $2.3m is expected in 2H21. Okay..
19. Valuations stretched.
Market cap is currently $300m. With $7.5m NPAT FY21f, we're paying a PE of x40. For a company with questionable growth and possible forthcoming impairments, that seems around x4 too much at least?
20. Purpose of the IPO.
I'd just conclude that I never understood the purpose of this IPO - the funds raised were 25% of total equity, 75% ownership retained. It seemed mainly just for liquidity for owners to sell out to. Smart, Bell Potter.. Smart.
If you enjoyed this, bash the like / retweet / follow buttons.
A deep dive per week is my commitment to FinTwit.
Questions and feedback always welcome. DM’s open. DYOR.
Angel Seafood $AS1 $AS1.AX is the largest oyster producer in Coffin Bay, making news for all the wrong reasons. A real microcap seeking to build scale, is now the time to swim against the tide? 🦪
Let’s take a deep dive. 👇
1. Investment thesis: Fast Grower.
✅Strong market for oysters
✅Revenue ramping up
✅CAPEX pulling back
✅Biomass in place for scaling
✅Skin in the game
🚨Food poisoning / sales suspension
2. Recently I looked at East 33 $E33 as an oyster play – sorry folks, it was a ruse!
That was my competitor research on Angel, which has taken a lot longer to get my head around due to the lack of information available.
East 33 $E33 $E33.AX is a premium Sydney Rock Oyster company that recently IPO’d. Substantive performance rights for management with a colourful history will likely drive a debt-fueled acquisition binge and short term shareholder returns.
Let’s take a deep dive. 👇
1. Investment thesis: Special situation.
✅Fast top-line growth driven by acquisitions.
✅Strong market conditions.
🚩Performance incentives for EBIT and share price growth.
🚩Debt financed.
🚩History of poor management.
2. East 33 farms native Sydney Rock Oysters – a premium product.
Vertically integrated, they have an export approved facility, export certificate, 195ha of farming licenses, and a nursery.
Costa Group Holdings $CGC $CGC.AX is Australia’s largest grower, packer and marketer of fresh fruit and vegetables. If you like your berries, mushrooms, tomatoes, avocados and citrus, maybe you’ll like the taste of Costa Group.
Let’s take a deep dive. 👇
1. Investment thesis:
✅Stalwart.
✅Market leading position in multiple growing consumer staples lines.
✅International expansion.
✅Generating decent operating free cash flow.
✅Trading at 52 week lows.
🚩CAPEX requirements
🚩Margins & growth rates.
2. Costa’s has grown over the years by modernising fruit and veg growing – bringing new varieties, 52-week availability to supermarkets, economies of scale, and locations near to major urban centres.
Wake up to find out Europe is in a gas crisis, Barnaby Joyce is worried about burping cows, and now you find your portfolio is underweight #seaweed ? Me too.
Let's take a look at 'Australian Seaweed As A Megatrend' 👇
1. Investment Thesis: Early stage investing in seaweed as a nascent industry with significant growth potential due to multiple mega trends (climate change, organic fertilizers, food security, and biopharma); moving from research into commercialisation.
2. What is seaweed?
Seaweed biomass can be used for an array of possible uses including food, animal feed, high-value pharmaceutical/ industrial compounds, biofuels, and fertilisers. It's grown in water, and has environmental benefits.
Genex $GNX $GNX.AX is a renewable energy developer with a focus on firming through pumped hydro and batteries. After 6yrs in the sin bin for epic delays, what's changed?
@ElephantCapita2 will also share his technical analysis to answer 'why now?'
Let’s take a deep dive.👇
1. Investment thesis: Turnaround / Asset play.
A high CAPEX company, in a growing sector, potential takeover target, progressed through multiple de-risking events, but due to failures since IPO in 2015 its priced markedly below fair value.
Potential to become a stalwart?🤷
2. Growing demand for renewables.
There’s a long tailwind of renewable energy growth, both as total consumption increases and renewables replace fossils. Wind, solar and other (inc. bioenergy) are growing, and Genex is positioning itself in that super fast growing space.
Avita Medical Inc. $AVH $AVH.AX is best known for its product ReCell $RCEL – spray on skin for burns victims. After a long history of innovation, commercial success has evaded this once-darling. Is this time different?
Let’s take a deep dive on 3 key metrics to watch.👇
1. Investment thesis: Fast grower / turnaround.
Innovative product with clear use case, competition falling way, optionality on new applications, top-line growth as adoption improves. Questionable management.
2. History in a nutshell. Founded as ‘Clinical Cell Culture’ in 1993 by Prof. Fiona wood who developed the tech with Marie Stone. First big test for ReCell was after the 2002 Bali Bombings treating the burn victims. renamed Avita in 2008.